The impact of clonal evolution on response to imatinib mesylate (Gleevec) in accelerated phase CML.

被引：0
|
作者：
O'Dwyer, ME
Mauro, MJ
Kurilik, G
Balleisen, S
Capdeville, R
Druker, BJ
机构：
[1] Oregon Hlth Sci Univ, Leukemia Ctr, Portland, OR 97201 USA
[2] Novartis Pharma AG, Basel, Switzerland
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
586
引用
收藏
页码：139A / 139A
页数：1
相关论文
共 50 条
  • [1] The impact of clonal evolution on response to imatinib mesylate (ST1571) in accelerated phase CML
    O'Dwyer, ME
    Mauro, MJ
    Kurilik, G
    Mori, M
    Balleisen, S
    Olson, S
    Magenis, E
    Capdeville, R
    Druker, BJ
    BLOOD, 2002, 100 (05) : 1628 - 1633
  • [2] A phase II trial of imatinib mesylate (Gleevec®) in myeloproliferative disorders other than CML.
    Kuriakose, P
    Shurafa, MS
    BLOOD, 2004, 104 (11) : 274B - 274B
  • [3] Pancytopenia, a complication of Gleevec in treatment of accelerated and chronic phase CML.
    Zalzaleh, G
    Jajeh, A
    BLOOD, 2003, 102 (11) : 310B - 310B
  • [4] Abnormal cytogenetic evolution in a case of CML treated by imatinib mesylate (Gleevec®).
    Besalduch, J
    Gutierrez, A
    Rosell, J
    Bernues, M
    Sampol, A
    BLOOD, 2002, 100 (11) : 331B - 331B
  • [5] The mechanism of geldanamycin compared with imatinib mesylate in CML.
    Sato, E
    Sugimoto, K
    Oshimi, K
    BLOOD, 2003, 102 (11) : 324B - 325B
  • [6] Preliminary evaluation of the combination of imatinib mesylate (Gleevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML.
    O'Dwyer, ME
    Mauro, MJ
    Kuyl, JM
    Paquette, R
    Sawyers, CL
    Druker, BJ
    BLOOD, 2001, 98 (11) : 846A - 846A
  • [7] Preliminary evaluation of the combination of imatinib mesylate (Gleevec) with low dose Ara-C as initial therapy for newly diagnosed chronic phase CML.
    Mauro, MJ
    O'Dwyer, ME
    Stone, RM
    Walker, T
    Wiese, A
    Druker, BJ
    BLOOD, 2002, 100 (11) : 165A - 165A
  • [8] Mutation detection in imatinib mesylate treated CML patients and clonal evolution.
    Bories, D
    Jodar, M
    Dapremont, V
    Debert, C
    Feroul, V
    Tulliez, M
    Perot, C
    van den Akker, J
    Maury, S
    Pautas, C
    Kuentz, M
    BLOOD, 2003, 102 (11) : 414A - 414A
  • [9] Pilot study of combination of imatinib mesylate and Trisenox® (As2O3) in patients with accelerated (AP) and blast phase (BP) CML.
    Ravandi-Kashani, F
    Ridgeway, J
    Nishimura, S
    Agarwal, M
    Feldman, L
    Salvado, A
    Kovak, MR
    Hoffman, R
    BLOOD, 2003, 102 (11) : 314B - 314B
  • [10] Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate
    O'Dwyer, ME
    Mauro, MJ
    Blasdel, C
    Farnsworth, M
    Kurilik, G
    Hsieh, YC
    Mori, M
    Druker, BJ
    BLOOD, 2004, 103 (02) : 451 - 455
12345